Neupulse.co

Neupulse occupies a specialized position at the intersection of neurotechnology, digital health and clinical research. Its core proposition is narrower than a general wellness wearable: the company is developing peripheral nerve stimulation for tic reduction, with a consumer-oriented wristband for Tourette syndrome and a separate clinical device progressing through regulatory approval. This creates a differentiated route between medication-based management, clinic-bound interventions and non-medical wellbeing products. The available comparable-company information does not identify credible named direct competitors; the listed similarity records are duplicates of Neupulse rather than independent businesses. As a result, its competitive position cannot be benchmarked reliably against specific companies. The more relevant comparison set is established Tourette’s treatment and support options, including pharmacological care, behavioral therapy and specialist clinical services. Neupulse’s stated differentiators are user control, non-invasive delivery and the potential for use outside a clinic, while its main constraints are regulatory clearance, clinical validation, reimbursement adoption and evidence of sustained real-world efficacy.

Neupulse’s trajectory shows a transition from university spin-out research toward commercialization. Founded on Feb 12, 2021, the company first accumulated $3.2 million in a seed round announced on Mar 18, 2024, followed by a further $642,645 on Jul 31, 2024. The Feb 12, 2026 seed financing of $4.09 million was the largest recorded round and increased cumulative funding to $7.93 million. The financing cadence suggests a capital-intensive development path rather than rapid software-style scaling. Product development progressed from demonstrating median-nerve stimulation effects in tic disorders to a digital wristband highlighted in 2024 and an official commercial launch with UK pre-orders on Oct 24, 2025. The company also lists a separate clinical device under development and regulatory review, indicating a two-track strategy spanning everyday use and healthcare applications. Deliveries had been targeted for June 2026 pending regulatory clearance, but public information does not establish whether that milestone was achieved.